INmune Bio (INMB) Competitors $7.47 -0.09 (-1.19%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$7.47 0.00 (0.00%) As of 04/15/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INMB vs. EOLS, AVDL, CRON, PRAX, OCS, CDXC, NUVB, ABCL, CVAC, and XNCRShould you be buying INmune Bio stock or one of its competitors? The main competitors of INmune Bio include Evolus (EOLS), Avadel Pharmaceuticals (AVDL), Cronos Group (CRON), Praxis Precision Medicines (PRAX), Oculis (OCS), ChromaDex (CDXC), Nuvation Bio (NUVB), AbCellera Biologics (ABCL), CureVac (CVAC), and Xencor (XNCR). These companies are all part of the "pharmaceutical products" industry. INmune Bio vs. Evolus Avadel Pharmaceuticals Cronos Group Praxis Precision Medicines Oculis ChromaDex Nuvation Bio AbCellera Biologics CureVac Xencor INmune Bio (NASDAQ:INMB) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, community ranking, profitability, valuation and analyst recommendations. Which has higher earnings and valuation, INMB or EOLS? INmune Bio has higher earnings, but lower revenue than Evolus. Evolus is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioINmune Bio$14K12,234.79-$30.01M-$2.11-3.54Evolus$266.27M2.44-$61.69M-$0.81-12.63 Which has more volatility & risk, INMB or EOLS? INmune Bio has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500. Comparatively, Evolus has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Do institutionals & insiders have more ownership in INMB or EOLS? 12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 35.2% of INmune Bio shares are owned by company insiders. Comparatively, 6.1% of Evolus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend INMB or EOLS? INmune Bio presently has a consensus price target of $22.80, indicating a potential upside of 205.22%. Evolus has a consensus price target of $24.67, indicating a potential upside of 141.12%. Given INmune Bio's stronger consensus rating and higher possible upside, research analysts clearly believe INmune Bio is more favorable than Evolus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Evolus 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer INMB or EOLS? In the previous week, Evolus had 15 more articles in the media than INmune Bio. MarketBeat recorded 19 mentions for Evolus and 4 mentions for INmune Bio. INmune Bio's average media sentiment score of 0.38 beat Evolus' score of 0.16 indicating that INmune Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evolus 4 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Is INMB or EOLS more profitable? INmune Bio has a net margin of 0.00% compared to Evolus' net margin of -22.33%. INmune Bio's return on equity of -117.48% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets INmune BioN/A -117.48% -78.96% Evolus -22.33%-847.60%-22.15% Does the MarketBeat Community favor INMB or EOLS? Evolus received 217 more outperform votes than INmune Bio when rated by MarketBeat users. However, 76.60% of users gave INmune Bio an outperform vote while only 73.08% of users gave Evolus an outperform vote. CompanyUnderperformOutperformINmune BioOutperform Votes14476.60% Underperform Votes4423.40% EvolusOutperform Votes36173.08% Underperform Votes13326.92% SummaryINmune Bio beats Evolus on 13 of the 19 factors compared between the two stocks. Remove Ads Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INMB vs. The Competition Export to ExcelMetricINmune BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$171.29M$2.90B$5.33B$7.57BDividend YieldN/A1.91%5.11%4.32%P/E Ratio-3.4331.0021.7317.82Price / Sales12,234.79441.16379.2094.61Price / CashN/A168.6838.1534.64Price / Book3.613.476.464.00Net Income-$30.01M-$72.06M$3.20B$247.23M7 Day Performance-2.10%3.17%2.86%1.45%1 Month Performance-6.04%-16.97%-8.55%-6.24%1 Year Performance-18.36%-29.07%10.47%0.60% INmune Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMBINmune Bio1.8617 of 5 stars$7.47-1.2%$22.80+205.2%-22.0%$171.29M$14,000.00-3.4310EOLSEvolus3.5092 of 5 stars$10.24-4.2%$24.67+140.9%-14.0%$651.13M$266.27M-11.25170Analyst RevisionPositive NewsGap DownAVDLAvadel Pharmaceuticals2.2544 of 5 stars$6.69-1.6%$19.88+197.1%N/A$646.45M$169.12M-8.4770Analyst RevisionGap DownCRONCronos Group1.5759 of 5 stars$1.68-1.8%$3.00+78.6%-29.5%$642.65M$117.62M-12.92450PRAXPraxis Precision Medicines2.9287 of 5 stars$31.53-3.4%$123.33+291.2%-44.4%$635.74M$8.55M-3.06110OCSOculis1.9829 of 5 stars$14.37-7.3%$29.50+105.3%+49.0%$627.42M$980,000.00-7.452High Trading VolumeCDXCChromaDex2.2758 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120Analyst ForecastNUVBNuvation Bio2.4722 of 5 stars$1.81+8.7%$8.75+384.8%-29.7%$611.32M$7.87M-0.8360Positive NewsHigh Trading VolumeABCLAbCellera Biologics2.1351 of 5 stars$2.05-1.9%$7.00+241.5%-41.9%$610.88M$28.83M-3.36500High Trading VolumeCVACCureVac3.3393 of 5 stars$2.65+2.3%$10.00+277.4%+21.9%$593.28M$543.28M4.82880Earnings ReportUpcoming EarningsShort Interest ↑XNCRXencor3.3808 of 5 stars$8.37-3.7%$34.38+310.7%-52.6%$589.77M$110.49M-2.62280High Trading Volume Remove Ads Related Companies and Tools Related Companies Evolus Competitors Avadel Pharmaceuticals Competitors Cronos Group Competitors Praxis Precision Medicines Competitors Oculis Competitors ChromaDex Competitors Nuvation Bio Competitors AbCellera Biologics Competitors CureVac Competitors Xencor Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INMB) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
